Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.40
-$0.36(-15.79%)
At close: 4:00 PM EST
$2.40
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.86
Previous CloseN/A
Volume307.14K
Average Volume (3M)3.94M
Market Cap
$328.07M
Enterprise Value$172.87M
Total Cash (Recent Filing)$132.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume4,473,836
30 Day Avg. Volume3,942,141
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$6.75Price Target Upside181.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a sizable equity base provide structural financial flexibility for a clinical-stage biotech. This reduces near-term default risk, supports ongoing R&D spending without immediate debt pressure, and increases optionality to pursue development milestones before needing urgent refinancing.
Partnership And Incremental FundingA development partnership that speeds Phase 2 enrollment and a direct $3M investment are structural positives: they lower operational execution risk, shorten development timelines, and modestly extend runway. External collaborator and investor backing also signal validation to future partners or financers.
Capital Raising FlexibilityA higher authorized share count and approved equity plans create lasting financing and compensation flexibility. For a pre-revenue developer this makes equity financing and stock-based retention easier, helping preserve cash for trials and enabling strategic partnerships without requiring immediate debt issuance.
Bears Say
Minimal Revenue And Widening LossesLack of meaningful revenue and expanding operating losses are structural constraints: the business cannot self-fund development, negative profitability compresses returns, and continued losses increase dependency on external capital until commercialization or partnership revenue emerges.
Persistent Cash BurnSustained negative operating and free cash flows force recurring financings and reduce strategic optionality. Even with some improvement in burn rate, ongoing outflows mean management must secure capital on a periodic basis, which can delay programs or impose costly financing terms if market conditions tighten.
Dilution Risk From Equity Authorizations And AwardsApproval of expanded authorized shares and broader equity programs creates a structural dilution pathway: the company is now positioned to issue material equity for funding or compensation. For investors this raises long-term per-share dilution risk and can pressure future per-share economics absent strong revenue progress.
Palisade Bio News
PALI FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was $0.53 and its highest was $2.85 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is $328.07M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 40 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.007.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 173,579,670 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.604%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.75 (181.25% Upside)
$6.75 (181.25% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 70%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $249.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 20.5%
Last 30 Days ▲ 20.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.99%
12-Months-Change
Fundamentals
Return on Equity
-36.79%
Trailing 12-Months
Asset Growth
1527.78%
Trailing 12-Months
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$6.75
▲(181.25% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
2.25% Insiders
4.62% Mutual Funds
<0.01% Other Institutional Investors
88.42% Public Companies and
Individual Investors